Abstract
Cancer is a major cause of deaths across the globe due to chemoresistance and lack of selective chemotherapy. Pyrido[2,3-d]pyrimidine is an emerging scaffold in medicinal chemistry having a broad spectrum of activities, including antitumor, antibacterial, CNS depressive, anticonvulsant, and antipyretic activities. In this study, we have covered different cancer targets, including tyrosine kinase, extracellular regulated protein kinases – ABL kinase, phosphatidylinositol-3 kinase, mammalian target of rapamycin, p38 mitogen-activated protein kinases, BCR-ABL, dihydrofolate reductase, cyclin-dependent kinase, phosphodiesterase, KRAS and fibroblast growth factor receptors, their signaling pathways, mechanism of action and structure–activity relationship of pyrido[2,3-d]pyrimidine derivatives as inhibitors of the above-mentioned targets. This review will represent the complete medicinal and pharmacological profile of pyrido[2,3-d]pyrimidines as anticancer agents, and will help scientists to design new selective, effective and safe anticancer agents.
Original language | English (US) |
---|---|
Pages (from-to) | 6872-6908 |
Number of pages | 37 |
Journal | RSC Advances |
Volume | 13 |
Issue number | 10 |
DOIs | |
State | Published - Feb 28 2023 |
Bibliographical note
KAUST Repository Item: Exported on 2023-03-06Acknowledgements: Authors are highly thankful to Central University of Punjab, DST-FIST, India, to infrastructural support for completion of this study. The APC was funded by King Abdullah University of Science and Technology (KAUST), Thuwal, Jeddah, Saudi Arabia.
ASJC Scopus subject areas
- General Chemical Engineering
- General Chemistry